Mar 16, 2016 9:48 EDT

Chemical Fingerprints Inc: The End to Alzheimer’s

iCrowdNewswire - Mar 16, 2016

Chemical Fingerprints Inc

The End to Alzheimer’s

Predicting the structure of these compounds has been the missing link in developing drugs that can eradicate these devastating diseases once and for all.

Chemical Fingerprints will be both licensing out our revolutionary software to fellow drug makers as well as working parallel with them to create anti-amyloid and anti-neurodegenerative drugs.

This is a real chance to save millions of lives around the world who suffer from neurodegenerative diseases. We are the only provider of a software anything close to the power of NeuroteX, and with it, Chemical Fingerprints is going to change the world.


Traditional methods of anti-amyloid and anti-neurodegenerative drug discovery involves developing drug molecules without knowing the structure of the beta amyloid. This has always been the critical crux of the problem.

Without knowing the structure, drug developers can’t target exactly where the amyloid molecules are binding. If they knew the structure, they could target the binding site, and develop drugs to increase effectiveness for that binding site type and specifically target the site of the bind.

Now they can, with NeuroteX.

Using NeuroteX software, researchers will significantly reduce the time and cost to develop new therapeutics. Our technology enables the biotechnology industry to rapidly discover patentable vaccines that can neutralize the amyloid fibrils and protein oligomers that lead to neurodegenerative diseases.

The platform consists of a standalone software designed specifically to address every step of the amyloid conformation in the drug development path, from data visualization to structural analysis and protein engineering.

The exact science is quite complex, but the simple version goes like this: neurodegenerative diseases like Alzheimer’s and Parkinson’s are caused by amyloid fibrils in the brain that should be soluble, but have become insoluble. NeuroteX will break down these structures so researchers can see exactly where that insoluble bind is — this has never been possible before.

Because they can now target a specific site, the process of testing specific drugs and treatments becomes much quicker and more efficient. The overall goal of these researchers is to discover the specific treatment that stimulates the activity of the brain’s immune cells which can then kill the mutated amyloid fibrils.

NeuroteX isn’t the cure for Alzheimer’s, Parkinson’s, and other neurological disorders, but it is the tool that will discover the cure.


So, when can we expect NeuroteX to be in use?


Over the next 2.5 years, we will go through 4 phases of development:

Phase I: Software development

Phase II: Cell line development for drug testing

Phase III: Drug development for Alzheimer’s and other neurodegenerative diseases

Phase IV: Small molecules as adjuvants for vaccine development

We are currently in the processes of patenting our software. Our goal is to give scientists the tools to efficiently and seamlessly test and discover their own anti-neurodegenerative drugs. We will be using our patent protected software to develop our own drug molecules as well. Once we prove the drug targets this specific site of binding, we can patent all of them.

To build the structure of a genetic fiber is a very hard task. For the past 5 years, we have been studying all neurological disorders and all structures. We’re now bringing it all together in one software package. Very few scientists have this knowledge and even fewer can apply it in a software. Chemical Fingerprints has cracked the code, now we just need help building it.

Next Steps: We need to hire two software programmers to develop the software and two research scientists for drug and cell culture development. With these hires, we can launch a beta of our software in 14-16 months.



Dr. Nataraj Sekhar Pagadala (Founder/CEO)         


  • 15 years of experience in computational drug discovery.
  • Software development for the prediction of amyloid fibrils and protein oligomers. 
  • Developed drugs for inhibition of amyloid fibrils and protein oligomers that are responsible for Alzheimer’s and other neurodegenerative diseases.


  • M.Sc in Biochemistry 
  • Advanced diploma course in Bioinformatics 
  • Ph.D. completed it in 2007


  • Research associate for Bioinformatics at the Global Institute for Biotechnology
  • Research associate for open-eye software from 2005 to 2007 
  • Postdoc on development of peptidomimetics for the inhibition of integrase with its cofactor LEDGF based on NMR studies 
  • Assistant professor in the department of Biotechnology, srikrishna Devaraya University, Andhra Pradesh, India from 2009-2010.
  • Six years of postdoc in computational drug discovery, modelling of amyloid fibrils and protein oligomers at the National Institute of nanotechnology, University of Alberta since May 2010. 
  • Research associate in Computational Drug Discovery at Applied Institute of Virology, Department of Medical Microbiology and Immunology at the University of Alberta, Edmonton, Canada.

Dr. Malla, R.V. Sudarshan, Ph.D 


  • Working as an assistant project scientist in the current lab at UCLA
  • Expertise in cell culture and animal study. 


  • Undergraduate degree: biology, biochemistry, and biotechnology 
  • M.Sc.: Molecular biology-Germany, 
  • Ph.D. Thesis: Role of autophagy in pancreatitis. 


  • Funding from AstraZeneca
  • Research experience: Various stages of preclinical trials of drug development and testing

Dr. Paramahamsa Maturu

  • Senior Research Scientist at the Department of Pediatrics, Section of Neonatology, Baylor College of Medicine and Texas Children’s Hospital in Houston, Texas.
  • Research areas: Role of inflammation, inflammatory microenvironment in initiation and progression of tumor. 
  • Postdoctoral training: University of Texas, MD Anderson Cancer Center, Houston, Texas, and Department of Tumor Immunology, James Graham Brown Cancer Center, Louisville, KY. 
  • Editorial board member of International Journal of Pediatric Research, Jacobs Journal of Molecular and Translational Medicine and Journal of Genetics and Genome Research. 
  • Senior review board member of various highly ranked journals like Plos One, Scientific Reports, Current Medicinal Chemistry, Cardiovascular Diabetology, Colloids and Surfaces B: Biointerfaces, Alcohol and Alcoholism, Neuro Toxicology Research, Food and Chemical Toxicology, Molecular and Cellular Biochemistry, Human Experimental Toxicology and many more in the scientific community. 
  • Published many papers in highly reputed and peer reviewed journals and received many awards. 
  • Senior member of Inflammation Research Association (IRA), American Society of Preventive Oncology (ASPO), and American Society of Nephrology (ASN).

Baskar Ramdas, Ph.D

  • Assistant Research Professor, Wells Center for Pediatric Research, IUPUI, Indianapolis
Contact Information:

Dr. Nataraj Sekhar Pagadala (Founder/CEO)
Dr. Malla, R.V. Sudarshan, Ph.D
Dr. Paramahamsa Maturu
Baskar Ramdas, Ph.D

View Related News >